NFKB1 and Miyoshi myopathy: Hence, our identification of CH60 as a novel coreceptor that exists on the plasma membrane to mediate matrikine-induced NF-κB signaling and drug resistance in MM cells is unprecedented and warrants further investigation to assess its potential as a biomarker for TME-mediated drug resistance and MM disease progression.